18.10.04 · organismal-bio / immunology

Vaccines and immunological memory: antigen presentation, B-cell clonal selection, and the principle of herd immunity

shipped3 tiersLean: none

Anchor (Master): Burnet 1957 Austr. J. Sci. 20:67 (clonal selection); Tonegawa 1976 PNAS 73:3628 (V-D-J); Doherty-Zinkernagel 1974 Nature 248:701 (MHC restriction); Karikó-Weissman 2005 Immunity 23:165 (modified-nucleoside mRNA)

Intuition Beginner

Vaccines teach the immune system to recognize a pathogen without causing the disease. The idea goes back to Edward Jenner in 1796. He noticed that milkmaids who caught cowpox, a mild illness, almost never caught smallpox, which was often fatal. He tested the connection on an eight-year-old boy named James Phipps: he infected the boy with cowpox, then later exposed him to smallpox. The boy did not get sick. The word vaccine comes from vacca, Latin for cow. That single experiment is the origin of every modern vaccine.

Modern vaccines work by the same principle. They show the immune system a harmless version of the pathogen — a piece of protein, a killed virus, a weakened live virus, or genetic instructions called mRNA that tell cells to make a piece of the pathogen. The immune system responds by producing antibodies and special cells called memory B cells that remember the pathogen for years. If the real pathogen enters later, those memory cells multiply and attack far faster than the first time, usually clearing it before symptoms appear.

Vaccines have prevented more deaths than nearly any other medical intervention. Smallpox killed roughly three hundred million people in the twentieth century alone and was declared eradicated in 1980 after a global vaccination campaign. Polio is near eradication. Measles deaths fell by about eighty percent worldwide between 2000 and 2020. Vaccines also protect people who cannot be vaccinated — newborns, the elderly, the immunocompromised — through a community effect called herd immunity, which works when enough of the population is immune that the pathogen cannot keep spreading.

Visual Beginner

The figure traces a vaccine antigen from injection to long-lived memory. An antigen-presenting cell takes up the antigen, breaks it into peptides, and displays them on MHC-II to a CD4 T-helper cell. With T-cell help, B cells enter the lymph-node germinal center, undergo somatic hypermutation and class-switch recombination, are selected by Tfh cells for high affinity, and exit as long-lived plasma cells (homing to bone marrow and secreting antibodies for years) or as circulating memory B cells.

A second panel plots the herd-immunity threshold $p_{c} = 1 - 1/ R_{0}$ against the basic reproduction number $R_{0}$ , marking measles ( $R_{0} \approx 18$ , $p_{c} \approx 94$ percent) and COVID-19 ( $R_{0} \approx 6$ , $p_{c} \approx 83$ percent).

The picture's two halves belong together: the cellular machinery on the left produces the memory compartments whose population-level coverage on the right determines whether an outbreak can grow.

Worked example Beginner

The Pfizer-BioNTech and Moderna COVID-19 vaccines, authorized in December 2020, were the first mRNA vaccines ever approved for humans.

Step 1. The SARS-CoV-2 virus was first sequenced in January 2020. Its outer surface is covered with a spike protein that locks onto human cells and lets the virus enter.

Step 2. Scientists designed an mRNA molecule encoding the spike. Decades earlier, Katalin Karikó and Drew Weissman had discovered that swapping in a modified nucleoside (pseudouridine) prevents the immune system from overreacting to the mRNA, a result they published in 2005. Without that 2005 paper, the 2020 vaccines would not have been possible.

Step 3. The mRNA is wrapped in tiny fat bubbles called lipid nanoparticles, which protect the mRNA and let it enter cells. After injection, some cells take up the mRNA, read it, and produce the spike protein. The immune system recognizes the spike as foreign and raises antibodies and memory B cells against it.

Step 4. Phase 3 trials in 2020 enrolled roughly thirty thousand volunteers per vaccine. Pfizer-BioNTech reported 95 percent efficacy against symptomatic COVID-19; Moderna reported 94 percent. The vaccines were authorized within roughly eleven months of the genome sequence — the fastest vaccine development in history.

Step 5. By 2023, mRNA COVID-19 vaccines had been given to billions of people. Mathematical models estimate that in the first year alone they prevented more than fourteen million deaths worldwide. Karikó and Weissman shared the 2023 Nobel Prize in Medicine.

What this tells us: long-running basic research on mRNA chemistry produced a flexible platform that allowed a new vaccine to be designed within days of a new virus being sequenced.

Check your understanding Beginner

Formal definition Intermediate+

A vaccine is a preparation of one or more antigenic substances, administered with the aim of inducing an adaptive immune response that protects against a specific pathogen without causing the disease. The classical taxonomy of platforms is: live-attenuated (MMR, yellow fever, oral polio), inactivated (Salk polio, rabies), toxoid (tetanus, diphtheria), subunit (Hepatitis B, HPV, Novavax COVID-19), conjugate (pneumococcal, Haemophilus influenzae b), viral-vector (Janssen/J&J, AstraZeneca; adenovirus-delivered gene), and mRNA (Pfizer-BioNTech, Moderna; lipid-nanoparticle-delivered mRNA) ^{[PlotkinVaccines]}.

Definition (antigen presentation). An antigen-presenting cell (APC; dendritic cells, macrophages, B cells) endocytoses the antigen, proteolytically cleaves it into short peptides (13-25 amino acids for MHC-II), and loads the peptides onto major histocompatibility complex class II (MHC-II) molecules in endosomal compartments. The peptide-MHC-II complex is then trafficked to the cell surface, where it is recognized by the T-cell receptor (TCR) of a CD4+ T-helper cell. Cytosolic antigens, including most viral proteins synthesized within the cell, are processed through the MHC-I pathway (8-11 amino acid peptides) and presented to CD8+ cytotoxic T cells. Cross-presentation allows certain APCs, especially dendritic cells, to route extracellular antigens into the MHC-I pathway, which is the mechanism by which viral-vector and mRNA vaccines, whose antigen is synthesized inside cells, still elicit CD8+ T-cell responses.

Definition (MHC restriction; Doherty-Zinkernagel 1974). T cells recognize antigen only when it is presented as a peptide bound to a self MHC molecule. The same peptide presented on a different (allogeneic) MHC is not recognized. This MHC restriction is the structural reason for the high diversity of MHC genes across a population: a wide MHC repertoire ensures that at least some individuals in the population can present any new pathogen's peptides ^{[DohertyZinkernagel1974]}.

Definition (clonal-selection theory; Burnet 1957). Each B lymphocyte expresses a unique, clonally distributed membrane-bound immunoglobulin (the B-cell receptor). Antigen binds a small subset of B-cell receptors with sufficient affinity; binding, together with cognate T-cell help, drives the selected B cells into clonal expansion and differentiation into two compartments: short-lived plasma cells that secrete large quantities of antibody, and memory B cells that persist long-term and re-activate on re-exposure. The diversity of B-cell receptors (estimated at more than $1 0^{11}$ distinct specificities per individual) is generated upstream by V-D-J recombination and is sharpened during the germinal-center reaction by somatic hypermutation ^[Burnet1957].

Definition (germinal-center reaction). Activated B cells migrate into lymph-node germinal centers, where they proliferate, undergo somatic hypermutation (targeted point mutations in the immunoglobulin variable-region genes, at a rate of approximately $1 0^{- 3}$ per base pair per division — roughly one million-fold above the genome-wide background), and are selected by follicular helper T (Tfh) cells on the basis of improved affinity for antigen. Surviving B cells also undergo class-switch recombination, replacing the heavy-chain constant region (IgM, IgD) with IgG, IgA, or IgE, which changes the antibody's effector function without altering its antigen specificity. Output cells exit as either long-lived plasma cells (homing to bone-marrow survival niches; secreting antibody for years to decades) or memory B cells (recirculating through blood and lymph; re-activating within days on re-exposure).

Definition (herd immunity). If a fraction $p$ of a population is immune (by vaccination or prior infection), the effective reproduction number is $R = (1 - p) R_{0}$ , where $R_{0}$ is the basic reproduction number. The critical vaccination fraction $p_{c}$ at which $R = 1$ — the threshold above which an infection cannot sustainably spread — is $p_{c} = 1 - 1/ R_{0}$ .

Counterexamples to common slips Intermediate+

"Vaccines cause the disease they prevent." Live-attenuated vaccines very rarely revert or cause mild symptoms (e.g., oral polio vaccine at roughly one vaccine-associated paralytic polio case per 750,000 first doses). Killed, subunit, and mRNA vaccines cannot cause the disease because they do not contain a viable pathogen.
"Natural infection always gives better immunity than vaccination." It sometimes gives a broader antibody response, but at the cost of disease severity. Vaccines are calibrated to deliver the antigenic signal without the pathogenic load. Large cohort studies (e.g., the 2021 Israeli BNT162b2 cohort) find mRNA-vaccinated individuals have comparable or lower risk of symptomatic disease than previously infected individuals, with substantially lower risk of severe disease.
"Vaccines cause autism." The 1998 Wakefield Lancet paper alleging a link between MMR and autism was retracted in 2010 after investigation found the data had been falsified. Large cohort studies (e.g., Madsen 2002 N. Engl. J. Med. 347:1477 on 537,303 children) find no association.
"mRNA vaccines alter your genome." The vaccine mRNA is translated in the cytoplasm and degraded within days. It cannot enter the nucleus, and even if it did, it lacks the reverse transcriptase and integration machinery needed to write into DNA.
"Herd immunity means individuals can safely skip vaccination." Herd immunity is a threshold, not a guarantee. Below the threshold, outbreaks occur; above it, transmission chains die out with high probability but not certainty. Free-riding reduces coverage and shifts the population towards the threshold. Measles outbreaks in countries where vaccination coverage dipped below 94 percent (the 2014-15 Disneyland outbreak; the 2017-19 Samoa outbreak with over 5,700 cases and 83 deaths) illustrate the cost.

Key mechanism: vaccine-induced immunological memory Intermediate+

Vaccine-induced immunological memory is mediated by two long-lived compartments — bone-marrow-resident long-lived plasma cells and recirculating memory B cells — that together produce a faster, larger, and higher-affinity antibody response on re-exposure than the primary naive response. The plasma-cell compartment provides a continuous baseline of secreted antibody (the steady-state serum IgG against, for example, tetanus toxoid declines with an estimated half-life of roughly 11 years in humans; Amanna-Slifka 2010 PLoS Biol.). The memory-B-cell compartment provides the rapid recall: on re-exposure, memory B cells differentiate into plasma cells within days (versus the one to two weeks the naive primary response takes to peak), and the antibodies they secrete have already been sharpened by the germinal-center reaction.

Theorem (two-compartment memory; Marshall-White 1975; Slifka-Ahmed 1998). Antigen-specific plasma cells and memory B cells persist without further antigen exposure, and on re-exposure the memory B cells produce a secondary antibody response that is faster, larger, and of higher mean affinity than the primary response.

Proof. The argument has four experimental legs.

(1) Persistence. Splenocytes from mice primed with a protein antigen months earlier can be transferred into naive recipients, who then mount a secondary response to challenge without further priming of the donor cells (Marshall-White 1975). Persistence is independent of ongoing antigen exposure, because depleting the immunizing antigen after priming does not abolish memory.

(2) Distinct compartments. Slifka-Ahmed 1998 Immunity 8:363 depleted plasma cells in mice (anti-CD138) while leaving memory B cells intact; serum antibody collapsed but secondary recall was preserved, demonstrating that the two compartments carry memory independently. Complementary memory-B-cell depletion experiments preserve standing antibody titres but abolish recall.

(3) Recall kinetics. In humans experimentally challenged with vaccinia or yellow fever vaccines, memory B cells expand within three to five days of re-exposure and produce a 10- to 100-fold rise in specific IgG, while the naive primary response to a novel antigen takes 7-14 days to reach detectable IgM. The recall is faster by roughly an order of magnitude.

(4) Affinity maturation. The antibodies secreted on recall have a mean affinity several-fold higher than those at the peak of the primary response, because the memory B cells are descendants of germinal-center B cells that have undergone somatic hypermutation and Tfh selection. This is the cellular signature of affinity maturation and the molecular reason secondary responses clear pathogens that primary responses would only control.

Together, (1)-(4) establish that the two compartments persist independently, are mechanistically distinct, and produce a recall response with the characteristic speed, magnitude, and affinity signature of immunological memory. $□$

Bridge. The two-compartment structure of memory builds toward 18.10.01 immunology's central division of adaptive immunity, in which long-lived plasma cells carry the standing antibody titre while memory B cells carry the recall potential, and appears again in 35.02.01 infectious-disease dynamics, where the standing titre sets the clinical protection threshold and the recall potential sets the speed of clearance. The foundational reason the system works is that the germinal-center reaction separates the recognition of antigen (clonal selection on the B-cell receptor) from the persistence of response (the plasma-cell and memory-B-cell compartments): this is exactly the design that allows vaccine antigen to be cleared within days while the immunity it induced lasts for years.

Exercises Intermediate+

Exercise 1 (easy, multiple choice).

The MMR vaccine (measles, mumps, rubella) is a live-attenuated vaccine. Which statement is most accurate?

A. It cannot cause any symptoms because it is a vaccine. B. It can rarely cause a mild febrile rash, but cannot cause measles itself in an immunocompetent person. C. It always causes a mild case of measles. D. It can integrate into the host genome.

Hint

Live-attenuated vaccines contain weakened versions of the live pathogen. They replicate in the host, which is why they produce strong immunity, but they also have the widest safety profile considerations.

Answer

B. Live-attenuated vaccines can cause mild symptoms (a low-grade fever or mild rash) because they replicate in the host, but the attenuated strain cannot cause classical measles in an immunocompetent host. The strain is genetically weakened so it does not spread systemically. Contraindicated in severely immunocompromised individuals and in pregnancy.

Exercise 5 (medium, symbolic).

The genome-wide point-mutation rate is roughly $1 0^{- 9}$ per base pair per cell division. The somatic hypermutation rate in the immunoglobulin variable region is roughly $1 0^{- 3}$ per base pair per division during the germinal-center reaction. Express the ratio (somatic hypermutation rate) / (genome-wide mutation rate) as a power of 10, and state in one sentence why this matters for the antibody response.

Hint

Compute $1 0^{- 3} /1 0^{- 9}$ and interpret what this means for how quickly B-cell receptor variants arise in the germinal center.

Answer

$1 0^{6}$ , a million-fold. Somatic hypermutation runs at a rate $1 0^{6}$ times the genome-wide background, targeted specifically to the immunoglobulin variable region. This elevated mutation rate is the engine of affinity maturation: it produces a large pool of B-cell receptor variants in each germinal-center reaction, on which Tfh-cell selection then acts, producing the characteristic 10- to 100-fold rise in mean antibody affinity over the course of a primary response.

Exercise 6 (medium, multiple choice).

Which output of the germinal-center reaction is the principal long-lived source of antibody that persists for years after vaccination?

A. Memory B cells recirculating in the blood. B. Long-lived plasma cells resident in bone-marrow survival niches. C. Follicular helper T cells in the lymph node. D. Naive B cells in the spleen.

Hint

Plasma cells secrete antibody; memory B cells carry receptors. Which compartment lives in a survival niche and secretes antibody continuously?

Answer

B. Long-lived plasma cells migrate to bone-marrow survival niches (defined by CXCL12-producing stromal cells and IL-6, APRIL signalling) where they can persist for years to decades, secreting antibody continuously. Memory B cells (option A) circulate but do not secrete antibody in quantity until re-activated; they carry the recall potential, not the standing titre.

Exercise 7 (hard, symbolic).

In an SIR epidemic model with susceptible $S$ , infected $I$ , and removed $R$ compartments, the dynamics are $\dot{S} = - β S I / N$ and $\dot{I} = β S I / N - γ I$ , where $N = S + I + R$ is the population and $γ$ is the recovery rate. Define $R_{0} = β / γ$ at the start of an epidemic (when $S \approx N$ ). Suppose a fraction $p$ of the population is vaccinated before the epidemic starts, so $S (0) = (1 - p) N$ . Show that the epidemic grows if and only if $(1 - p) R_{0} > 1$ , and hence that the critical vaccination fraction is $p_{c} = 1 - 1/ R_{0}$ .

Hint

Substitute $S (0) = (1 - p) N$ into the early-epidemic condition $\dot{I} > 0$ and rearrange.

Answer

At $t = 0$ with $S (0) = (1 - p) N$ and $I (0)$ small, the rate of change of $I$ is

\dot{I}_{t = 0} = \frac{β S ( 0 ) I ( 0 )}{N} - γ I (0) = I (0) (β (1 - p) - γ) .

The infected compartment grows ( $\dot{I} > 0$ ) if and only if $β (1 - p) > γ$ , i.e. $(1 - p) R_{0} > 1$ where $R_{0} = β / γ$ . The critical vaccination fraction is the value of $p$ at which $\dot{I} = 0$ :

(1 - p_{c}) R_{0} = 1 ⟹ p_{c} = 1 - \frac{1}{R _{0}} .

For $R_{0} = 18$ (measles), $p_{c} \approx 0.944$ . For $R_{0} = 6$ (delta-variant SARS-CoV-2), $p_{c} \approx 0.833$ . For $R_{0} = 1.5$ (seasonal influenza), $p_{c} \approx 0.33$ .

Exercise 8 (hard, numeric).

A country has 92 percent measles vaccination coverage. Measles has $R_{0} = 18$ . Assuming vaccine efficacy of 100 percent for simplicity, estimate (a) the effective reproduction number $R$ in this population; (b) whether an introduced case triggers a growing epidemic; (c) the minimum coverage required for herd immunity.

Hint

Use $R = (1 - p) R_{0}$ with $p = 0.92$ . Compare $R$ to 1 to decide epidemic growth. Set $R = 1$ to find $p_{c}$ .

Answer

(a) $R = (1 - 0.92) \times 18 = 0.08 \times 18 = 1.44$ . (b) Since $R = 1.44 > 1$ , an introduced case triggers a growing epidemic on average. Each infected individual infects approximately 1.44 others in this population. (c) The threshold is $p_{c} = 1 - 1/18 \approx 0.944$ , or 94.4 percent. The 92 percent coverage falls below the threshold by about 2.4 percentage points — enough to permit sustained transmission. This is the structural reason that measles outbreaks reappear whenever coverage dips even slightly below the threshold.

Advanced results Master

Theorem 1 (Burnet 1957 clonal-selection theory; 1960 Nobel). Each B lymphocyte synthesizes a single, unique immunoglobulin receptor before any encounter with antigen. Antigen selects, from the pre-existing repertoire, the small subset of B cells whose receptors bind it with sufficient affinity; the selected cells then proliferate clonally and differentiate into antibody-secreting plasma cells and memory B cells. The theory predicts monoclonality of each B cell (one receptor per cell) and antigen-driven selection over instruction. Jerne 1955 had foreshadowed a selection mechanism, but Burnet 1957 Austr. J. Sci. 20:67 made it testable ^[Burnet1957].

Theorem 2 (Tonegawa 1976 V-D-J recombination; 1987 Nobel). The immunoglobulin heavy-chain locus is a discontinuous gene: separate clusters of V (variable), D (diversity), and J (joining) gene segments recombine at the DNA level in developing B cells. Somatic recombination of one V, one D, and one J segment, with random nucleotide additions and deletions at the junctions (TdT, Artemis), generates the primary antibody repertoire. This resolves the paradox identified by Dreyer-Bennett 1965: how a finite mammalian genome encodes more than $1 0^{11}$ distinct antibodies ^{[Tonegawa1976]}.

Theorem 3 (Doherty-Zinkernagel 1974 MHC restriction; 1996 Nobel). Cytotoxic T lymphocytes from a mouse infected with lymphocytic choriomeningitis virus (LCMV) kill virus-infected target cells only when the target shares an MHC class I haplotype with the responding T cell. T cells thus recognize a self-MHC + foreign-peptide complex, not foreign antigen alone. This reframed the T-cell receptor as a dual-specificity receptor and explains why the MHC locus (the HLA cluster in humans) is the most polymorphic in the genome ^{[DohertyZinkernagel1974]}.

Theorem 4 (MacLennan 1994 germinal-center kinetics; Muramatsu 2000 AID). Germinal centers are the site of two coupled processes: somatic hypermutation (introduced by AID, activation-induced cytidine deaminase, on the immunoglobulin variable region; Muramatsu 2000 Cell 102:553) and selection by follicular helper T (Tfh) cells for high-affinity B-cell receptors. Each germinal-center B cell divides every 6-12 hours, mutates its receptor at each division, and is rescued from apoptosis by Tfh-derived survival signals only if its mutated receptor binds antigen better than its competitors. Over one to two weeks, the mean affinity of the output population rises 10- to 100-fold — the molecular basis of affinity maturation.

Theorem 5 (Slifka-Ahmed 1998 long-lived plasma cells). Plasma-cell depletion in mice (anti-CD138) abolishes serum antibody titres but leaves memory B cells intact; on re-challenge, those memory B cells regenerate a full secondary antibody response. Conversely, memory-B-cell depletion leaves plasma-cell-derived antibody titres intact but abolishes recall. Memory is therefore distributed across two independent compartments with distinct kinetics: plasma cells (long-lived, antibody-secreting, bone-marrow-resident) and memory B cells (long-lived, receptor-bearing, recirculating). The estimated half-life of plasma-cell-derived serum IgG in humans is roughly 10 years for most antigens (Amanna-Slifka 2010 PLoS Biol.).

Theorem 6 (Karikó-Weissman 2005 modified-nucleoside mRNA; 2023 Nobel). Exogenous mRNA introduced into mammalian cells triggers a strong innate-immune response through pattern-recognition receptors (TLR3, TLR7, TLR8, RIG-I) that read unmodified ribonucleotides as viral. Karikó and Weissman showed that substituting modified nucleosides — most prominently pseudouridine — suppresses TLR signalling and dramatically increases mRNA translation in vivo. The 2005 Immunity paper provided the chemical key that made lipid-nanoparticle-delivered mRNA a viable vaccine platform, leading directly to the Pfizer-BioNTech and Moderna COVID-19 vaccines authorized in December 2020 ^{[KarikoWeissman2005]}.

Theorem 7 (Polack 2003 measles memory B cells). A measles outbreak in a previously vaccinated population allowed direct measurement of the recall response: memory B cells differentiated into antibody-secreting cells within 3-5 days, producing a roughly 50-fold rise in measles-specific IgG. The rapid, antigen-specific IgG-dominated response (rather than the slow IgM-dominated primary response) is the clinical signature of immunological memory and the mechanism by which a vaccinated person clears the virus before symptoms develop.

Synthesis. The clonal-selection framework builds toward 18.10.01 the chapter's central division of adaptive immunity into humoral (B-cell) and cell-mediated (T-cell) arms, and appears again in 35.02.01 infectious-disease epidemiology, where the population-level herd-immunity threshold $p_{c} = 1 - 1/ R_{0}$ is the formal expression of individual immune protection scaled up. The foundational reason vaccines work at all is that the immune system maintains a pre-existing repertoire of more than $1 0^{11}$ B-cell receptors (Tonegawa 1976), from which antigen selects and expands the matching clone (Burnet 1957); this is exactly the architecture that allows a single dose of antigen to produce two long-lived compartments (Slifka 1998) whose output covers the timescale of decades. Putting these together with the Karikó-Weissman 2005 mRNA chemistry that lets any protein sequence be presented to the immune system within weeks, the central insight is that vaccination is the engineering exploitation of clonal selection: the bridge is between the molecular logic of V-D-J recombination at the cellular level and the population-level logic of the SIR epidemic, and the pattern recurs in every new platform — live-attenuated, subunit, viral-vector, mRNA — which differs in how antigen is delivered but converges on the same germinal-center machinery.

Full proof set Master

Proposition 1 (herd-immunity threshold). For an SIR epidemic with $R_{0} = β / γ$ , vaccination of a fraction $p$ of the population before the epidemic reduces the effective reproduction number to $R = (1 - p) R_{0}$ . The epidemic cannot grow if $R \leq 1$ , which gives the critical vaccination fraction $p_{c} = 1 - 1/ R_{0}$ .

Proof. With $S (0) = (1 - p) N$ , $I (0)$ small, and $R (0) = pN$ , the early-epidemic infected rate is $\dot{I} (0) = (β S (0) / N - γ) I (0) = γ ((1 - p) R_{0} - 1) I (0)$ . The infected compartment shrinks if and only if $(1 - p) R_{0} \leq 1$ . Solving the boundary case gives $p_{c} = 1 - 1/ R_{0}$ . Below $p_{c}$ , an epidemic grows exponentially with rate $r = γ ((1 - p) R_{0} - 1)$ ; at or above $p_{c}$ , introduced cases produce only stuttering chains that die out. $□$

Proposition 2 (antibody diversity lower bound from V-D-J combinatorics). The number of distinct B-cell receptors generated by combinatorial V-D-J joining alone is bounded below by $V_{H} D_{H} J_{H} \cdot V_{κ} J_{κ}$ , where $V_{H}, D_{H}, J_{H}$ are the heavy-chain segment counts and $V_{κ}, J_{κ}$ are the kappa light-chain segment counts. For the human loci this product exceeds $1 0^{6}$ .

Proof. The heavy-chain locus contains $V_{H} \approx 50$ , $D_{H} \approx 23$ , $J_{H} \approx 6$ functional segments; the kappa light-chain locus contains $V_{κ} \approx 40$ , $J_{κ} \approx 5$ . Each B cell picks one of each segment independently at the DNA level (Tonegawa 1976). The number of heavy-chain variable regions is $V_{H} D_{H} J_{H} = 50 \cdot 23 \cdot 6 = 6, 900$ . The number of kappa light-chain variable regions is $V_{κ} J_{κ} = 40 \cdot 5 = 200$ . Because each B cell pairs one heavy with one light chain, and the two rearrange independently, the combinatorial diversity is $6, 900 \cdot 200 = 1.38 \times 1 0^{6}$ . Junctional diversity (random nucleotide additions and deletions at the V-D, D-J, and V-J joins, introduced by Artemis and TdT) and somatic hypermutation in subsequent germinal-center reactions each multiply this baseline by several orders of magnitude, giving the estimated $> 1 0^{11}$ total repertoire per individual. $□$

Connections Master

Immunology survey 18.10.01. The chapter anchor: 18.10.01 lays out the innate-versus-adaptive division, the immune cells (B, T, NK, dendritic), and the cytokine signalling framework on which this unit's depth treatment of vaccine-induced memory depends. The clonal-selection theory and the germinal-center reaction referenced here are introduced there as the mechanism that produces adaptive immunity; this unit unpacks the cellular compartments (long-lived plasma cells and memory B cells) and the population-level consequence (herd immunity).
Innate immunity at the molecular level 17.10.01. Vaccines do not bypass the innate system; they depend on it. Every vaccine is formulated or co-administered with adjuvants (alum, MF59, AS01) that engage innate pattern-recognition receptors (TLRs, NLRs, inflammasomes) in dendritic cells. That innate signal is the licence the dendritic cell needs to migrate to the draining lymph node and activate T cells. The molecular detail of TLR signalling and inflammasome activation treated in 17.10.01 is the upstream chemical basis of the adaptive response induced here.
Infectious disease survey 35.02.01. The clinical counterpart: 35.02.01 catalogues the pathogens, their transmission routes, and their basic reproduction numbers $R_{0}$ . The herd-immunity threshold $p_{c} = 1 - 1/ R_{0}$ derived in this unit is the population-level link between individual immune protection and the epidemiology of outbreaks that 35.02.01 surveys. Vaccine-preventable diseases — measles, polio, diphtheria, tetanus, pertussis, Hib, hepatitis B — are the concrete targets to which the formalism applies.

Historical & philosophical context Master

Edward Jenner's 1796 experiment — infecting the eight-year-old James Phipps with cowpox and challenging him with smallpox — was reported in his 1798 Inquiry into the Causes and Effects of the Variolae Vaccinae ^[Jenner1798]. Jenner did not know what a virus was, what an antibody was, or why his procedure worked. Nearly a century passed before Louis Pasteur, working from germ theory, attenuated rabies virus in dried rabbit spinal cords and vaccinated Joseph Meister in 1885 — the first laboratory-attenuated vaccine. Emil von Behring and Shibasaburo Kitasato demonstrated in 1890 that immunity could be transferred by serum (antibodies); von Behring received the first Nobel Prize in Physiology or Medicine in 1901. Paul Ehrlich's side-chain theory (1900; 1908 Nobel) was the first conceptual model of antibody formation, foreshadowing clonal selection.

The clonal-selection theory was published by Frank Macfarlane Burnet in 1957 ^[Burnet1957] and independently proposed by David Talmage and Joshua Lederberg the same year; Burnet received the 1960 Nobel Prize. Susumu Tonegawa's 1976 PNAS paper demonstrated that immunoglobulin genes rearrange at the DNA level ^{[Tonegawa1976]}, explaining the genetic basis of antibody diversity (1987 Nobel). Peter Doherty and Rolf Zinkernagel's 1974 MHC-restriction discovery ^{[DohertyZinkernagel1974]} reframed T-cell recognition (1996 Nobel). Katalin Karikó and Drew Weissman's 2005 Immunity paper ^{[KarikoWeissman2005]} identified modified nucleosides as the key to non-immunostimulatory mRNA, the foundation on which the Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines were built within eleven months of the SARS-CoV-2 genome sequence; Karikó and Weissman shared the 2023 Nobel Prize in Physiology or Medicine.

Bibliography Master

@book{Jenner1798,
  author = {Jenner, Edward},
  title = {An Inquiry into the Causes and Effects of the Variolae Vaccinae},
  publisher = {Sampson Low},
  address = {London},
  year = {1798},
}

@article{Burnet1957,
  author = {Burnet, F. M.},
  title = {A modification of {J}erne's theory of antibody production using the concept of clonal selection},
  journal = {Australian Journal of Science},
  volume = {20},
  pages = {67--69},
  year = {1957},
}

@article{Tonegawa1976,
  author = {Tonegawa, S.},
  title = {Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions},
  journal = {Proceedings of the National Academy of Sciences USA},
  volume = {73},
  number = {1},
  pages = {3628--3632},
  year = {1976},
}

@article{DohertyZinkernagel1974,
  author = {Doherty, P. C. and Zinkernagel, R. M.},
  title = {Restriction of in vitro {T} cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system},
  journal = {Nature},
  volume = {248},
  pages = {701--702},
  year = {1974},
}

@article{KarikoWeissman2005,
  author = {Karik\'{o}, K. and Buckstein, M. and Ni, H. and Weissman, D.},
  title = {Suppression of {RNA} recognition by {T}oll-like receptors: the impact of nucleoside modification and the evolutionary origin of {RNA}},
  journal = {Immunity},
  volume = {23},
  number = {2},
  pages = {165--175},
  year = {2005},
}

@article{Slifka1998,
  author = {Slifka, M. K. and Antia, R. and Whitmire, J. K. and Ahmed, R.},
  title = {Humoral immunity due to long-lived plasma cells},
  journal = {Immunity},
  volume = {8},
  number = {3},
  pages = {363--372},
  year = {1998},
}

@article{AmannaSlifka2010,
  author = {Amanna, I. J. and Carlson, N. E. and Slifka, M. K.},
  title = {Duration of humoral immunity to common viral and bacterial vaccines},
  journal = {PLoS Biology},
  volume = {5},
  pages = {e1000218},
  year = {2010},
}

@article{Muramatsu2000,
  author = {Muramatsu, M. and Kinoshita, K. and Fagarasan, S. and Yamada, S. and Shinkai, Y. and Honjo, T.},
  title = {Class switch recombination and hypermutation require activation-induced cytidine deaminase ({AID}), a potential {RNA} editing enzyme},
  journal = {Cell},
  volume = {102},
  number = {5},
  pages = {553--563},
  year = {2000},
}

@article{Madsen2002,
  author = {Madsen, K. M. and Hviid, A. and Vestergaard, M. and Schendel, D. and Wohlfahrt, J. and Thorsen, P. and Olsen, J. and Melbye, M.},
  title = {A population-based study of measles, mumps, and rubella vaccination and autism},
  journal = {New England Journal of Medicine},
  volume = {347},
  number = {19},
  pages = {1477--1482},
  year = {2002},
}

@book{MurphyWeaver2022,
  author = {Murphy, K. and Weaver, C.},
  title = {Janeway's Immunobiology},
  edition = {10},
  publisher = {Garland Science},
  address = {New York},
  year = {2022},
}

@book{PlotkinVaccines,
  author = {Plotkin, S. A. and Orenstein, W. A. and Offit, P. A. and Edwards, K. M.},
  title = {Plotkin's Vaccines},
  edition = {8},
  publisher = {Elsevier},
  address = {Philadelphia},
  year = {2022},
}

@book{Offit2008,
  author = {Offit, P. A.},
  title = {Autism's False Prophets: Bad Science, Risky Medicine, and the Search for a Cure},
  publisher = {Columbia University Press},
  address = {New York},
  year = {2008},
}

Prerequisites

18.10.01

Tier anchors

beginner: Paul Offit — Autism's False Prophets (Columbia University Press, 2008); Khan Academy — Types of immune responses; Campbell Biology Ch. 43
intermediate: Murphy-Weaver — Janeway's Immunobiology, 10th ed. (Garland Science, 2022); Abbas-Lichtman-Pillai — Basic Immunology, 6th ed. (Elsevier, 2022)
master: Burnet 1957 Austr. J. Sci. 20:67 (clonal selection); Tonegawa 1976 PNAS 73:3628 (V-D-J); Doherty-Zinkernagel 1974 Nature 248:701 (MHC restriction); Karikó-Weissman 2005 Immunity 23:165 (modified-nucleoside mRNA)

References

Jenner, E. — An Inquiry into the Causes and Effects of the Variolae Vaccinae · Sampson Low (London, 1798); the 1796 cowpox-smallpox experiment on James Phipps
Burnet, F. M. — A modification of Jerne's theory of antibody production using the concept of clonal selection · Australian Journal of Science 20 (1957) 67-69; the clonal-selection theory
Tonegawa, S. — Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions · Proc. Natl. Acad. Sci. USA 73 (1976) 3628-3632; V-D-J recombination
Karikó, K., Buckstein, M., Ni, H. & Weissman, D. — Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA · Immunity 23 (2005) 165-175; modified-nucleoside mRNA
Doherty, P. C. & Zinkernagel, R. M. — Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system · Nature 248 (1974) 701-702; MHC restriction of T-cell recognition
Murphy, K. & Weaver, C. — Janeway's Immunobiology, 10th ed. · Garland Science (2022); Ch. 1-16

Estimated time

beginner: 25m
intermediate: 50m
master: 85m